Filing Details
- Accession Number:
- 0001225208-21-013883
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-15 17:40:30
- Reporting Period:
- 2021-11-11
- Accepted Time:
- 2021-11-15 17:40:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 78003 | Pfizer Inc | PFE | Pharmaceutical Preparations (2834) | 135315170 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1437590 | Mikael Dolsten | Pfizer Inc.-Corp. Secretary 235 East 42Nd St. New York NY 10017 | President R&D | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-11-11 | 76,135 | $22.89 | 216,093 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-11-11 | 64,841 | $27.34 | 280,934 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-11-11 | 58,572 | $25.60 | 339,506 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-11-11 | 2,124 | $50.34 | 337,382 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-11 | 2,301 | $50.32 | 335,081 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-11 | 3,197 | $50.29 | 331,884 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-11 | 3,396 | $50.31 | 328,488 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-11 | 5,227 | $50.29 | 323,261 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-11 | 6,708 | $50.33 | 316,553 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-11-11 | 36,711 | $50.28 | 279,842 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Phantom Stock Units | Disposition | 2021-11-11 | 47,828 | $50.18 | 47,828 | $0.00 |
| Common Stock | Stock Appreciation Rights | Disposition | 2021-11-11 | 153,789 | $0.00 | 153,789 | $27.34 |
| Common Stock | Stock Appreciation Rights | Disposition | 2021-11-11 | 145,970 | $0.00 | 145,970 | $22.89 |
| Common Stock | Stock Appreciation Rights | Disposition | 2021-11-11 | 127,160 | $0.00 | 127,160 | $25.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 71,314 | No | 4 | I | Direct | ||
| 0 | 2020-02-23 | 2022-02-23 | No | 4 | M | Direct |
| 0 | 2019-02-25 | 2023-02-25 | No | 4 | M | Direct |
| 0 | 2018-02-26 | 2022-02-26 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,803 | Indirect | By Rule 16b-3 Plan |
Footnotes
- Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $44.58)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant.
- Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in Pfizer common stock price (20 trading day average ending on the exercise date (Election Price of $44.58)) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant.
- Each unit represents one phantom share of common stock.
- The reporting person diversified shares held in the Pfizer Inc. Deferred Compensation Plan ("Plan") pursuant to the Plan's diversification provision into an alternate investment option(s) under the Plan.
- The units, held under the Deferred Compensation Plan, are paid in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
Billionaire Hedge Funds
